Chanos says he's still short Valeant (VRX), started in low $100s - CNBC
- S&P 500 ends higher as markets weigh rising yields, upbeat corporate results
- Meta Platforms reports softer Q2 revenue guidance on plans to boost spending on AI
- IBM (IBM) announces mixed Q1 results, HashiCorp acquisition; shares down
- Equities mixed as investors eye earnings; yen on intervention watch
- ServiceNow (NOW) stock falls as refreshed subscription outlook trails estimates
- Fisker (FSR) Appoints Michael Healy as Chief Restructuring Officer
- Seagate Technology (STX) Enters $600M Asset Purchase Agreement with Avago
- Meta Platforms (META) Tops Q1 EPS by 39c, Offers Guidance
- Hasbro (HAS) brand strength sees earnings top expectations
- IBM (IBM) announces mixed Q1 results, HashiCorp acquisition; shares down
- After-hours movers: Meta, Ford, IBM, ServiceNow and more
- Midday movers: Tesla, Boeing rise; Uber, Old Dominion Freight fall
- After-hours movers: Tesla, Texas Instruments, Seagate, Visa and more
- Midday movers: PepsiCo, JetBlue fall; GM, Danaher and UPS rise
- After-hours movers: Cadence Design Systems, Cleveland-Cliffs, Riot Platforms, and more
UPDATE: Bill Miller Says Valeant (VRX) is One of His Biggest Long Positions - Delivering Alpha Conf.
September 13, 2016 12:14 PM EDT(Updated - September 13, 2016 12:19 PM EDT)
Bill Miller says Valeant Pharma (NYSE: VRX) is one of his biggest long positions, according to Bloomberg.
UPDATE - Miller sees Valeant as a "busted roll-up" that could climb 25 - 30 percent in... More
Valeant Pharma (VRX) CEO Papa: Dermatology has Been 'A Challenge' for Us - Bloomberg
September 13, 2016 9:24 AM EDTValeant Pharma (NYSE: VRX) CEO Joe Papa commented today that dermatology has been "a challenge" for us, according o Bloomberg.
Papa also commented:
We're seeing growth in new prescriptions for SalixWe plan to spend more in R&D in... MoreEyegate Pharma (EYEG) Announces Receipt of Additional Milestone Payment from Valeant (VRX) Related to EGP-437 License
September 12, 2016 8:34 AM EDTEyeGate Pharmaceuticals, Inc. (Nasdaq: EYEG) announced that it has received an additional development milestone from a subsidiary of Valeant Pharmaceuticals International, Inc. (NYSE: VRX) under the Companys License Agreement with Valeant, pursuant to which EyeGate has granted Valeant... More
Activist Starboard demands rapid changes at Perrigo
September 12, 2016 7:16 AM EDTBy Michael Flaherty
NEW YORK (Reuters) - Activist shareholder Starboard Value LP on Monday disclosed a 4.6 percent stake in Perrigo Co Plc (NYSE: PRGO) and said the Dublin-based drugmaker must make immediate improvements to turn around its sagging stock price.
Shares of Perrigo, whose market capitalization is around $13 billion, surged 7.3 percent to $95.15 in midday trading.
The hedge fund delivered a scathing letter to Perrigo's chief executive officer, John Hendrickson, and its board on Monday, criticizing their performance since the company spurned a seven-month takeover effort by generic drug maker Mylan NV (NASDAQ:... More
Stocks with call strike movement; TWTR TSLA
September 9, 2016 11:16 AM EDTRT Options Scanner shows: Twitter (NYSE: TWTR) December 23 call option implied volatility increased 2% to 71, Valeant Pharma (NYSE: VRX) January 35 call option implied volatility increased 2% to 71.
... More